A groundbreaking medication , retatrutide, is sparking considerable anticipation within the Australian weight loss community. Created by Eli Lilly , this twin GIP and GLP-1 agonist appears to offer more significant outcomes than existing therapies. Preliminary medical research have shown remarkable reductions in physical mass, indicating the potent